Sanofi - ADR (SNY): Price and Financial Metrics
Sanofi - ADR (SNY)
Today's Latest Price: $51.37 USD
Updated Aug 13 5:46pm
Add SNY to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SNY Stock Summary
- SNY has a market capitalization of $129,871,362,335 -- more than approximately 98.57% of US stocks.
- With a year-over-year growth in debt of 54.84%, Sanofi's debt growth rate surpasses 81.58% of about US stocks.
- The volatility of Sanofi's share price is greater than that of only 1.34% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to SNY, based on their financial statements, market capitalization, and price volatility, are PFE, DSGX, TEL, NVS, and EW.
- SNY's SEC filings can be seen here. And to visit Sanofi's official web site, go to www.sanofi.com.
SNY Stock Price Chart Technical Analysis Charts
SNY Price/Volume Stats
| Current price | $51.37 | 52-week high | $55.00 |
| Prev. close | $51.79 | 52-week low | $37.62 |
| Day low | $51.18 | Volume | 623,741 |
| Day high | $51.51 | Avg. volume | 1,965,751 |
| 50-day MA | $51.66 | Dividend yield | 2.26% |
| 200-day MA | $48.64 | Market Cap | 128.64B |
Sanofi - ADR (SNY) Company Bio
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.
SNY Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $51.37 | $66.51 | 31% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Sanofi. To summarize, we found that Sanofi ranked in the 53th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 31.5%. The most interesting components of our discounted cash flow analysis for Sanofi ended up being:
- The compound growth rate in the free cash flow of Sanofi over the past 4.99 years is 0.02%; that's higher than only 22.35% of free cash flow generating stocks in the Healthcare sector.
- Sanofi's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 9.13% of tickers in our DCF set.
- SNY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than only 9.13% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 28% |
| 1% | 30% |
| 2% | 31% |
| 3% | 32% |
| 4% | 33% |
| 5% | 35% |
MGLN, HAE, UNH, LH, and ACIU can be thought of as valuation peers to SNY, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...